Fucoxanthin (all-trans-Fucoxanthin) |
| Catalog No.GC31364 |
Fucoxanthin (all-trans-Fucoxanthin) is a naturally occurring carotenoid widely distributed in edible brown seaweed and diatoms.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3351-86-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fucoxanthin (all-trans-Fucoxanthin) is a naturally occurring carotenoid widely distributed in edible brown seaweed and diatoms[1]. Fucoxanthin is highly unsaturated, its molecular structure is unstable and very active. Fucoxanthin has four isomers, namely all-trans Fucoxanthin (the main isomer in the natural environment), 9′-cis Fucoxanthin, 13-cis Fucoxanthin, and 13′-cis Fucoxanthin[2]. Fucoxanthin can be used in research on obesity, anti-diabetes, antioxidants, inflammation, and cancer[3]. Fucoxanthin can effectively inhibit the activity of Mycobacterium tuberculosis aromatic amine N-acetyltransferase (TBNAT), with an IC50 value of 4.8µM[4].
In vitro, treatment of B16-F10 cells with Fucoxanthin (0-30μM) for 24h inhibited cell invasion, migration and adhesion in a dose-dependent manner, and inhibited the expression of transfer factors MMP-9, CD44 and CXCR4[5]. Treatment of cervical cancer HeLa and SiHa cells with Fucoxanthin (0-25µM) for 24h inhibited cell proliferation and induced cell cycle arrest at the G0/G1 phase[6]. Treatment of RAW264.7 cells with Fucoxanthin (0-100µg/mL) for 24h inhibited the expression of intracellular TNF-α, PGE2, iNOS and COX-2 proteins in a dose-dependent manner[7].
In vivo, oral administration of Fucoxanthin (25, 50mg/kg) to mice with cadmium chloride-induced renal injury for 14 days promoted the recovery of renal function, renal cell microstructure and ultrastructure, significantly reduced blood urea nitrogen (BUN), kidney injury marker 1 (KIM1) and neutrophil gelatinase-associated lipocalin (NGAL) levels in mice, and increased peroxidase (POD), superoxide dismutase (SOD), catalase (CAT) and ascorbate peroxidase (APX) levels[8].
References:
[1] Din N A S, Mohd Alayudin A S, Sofian-Seng N S, et al. Brown algae as functional food source of fucoxanthin: A review[J]. Foods, 2022, 11(15): 2235.
[2] Pajot A, Hao Huynh G, Picot L, et al. Fucoxanthin from algae to human, an extraordinary bioresource: Insights and advances in up and downstream processes[J]. Marine drugs, 2022, 20(4): 222.
[3] Miyashita K, Beppu F, Hosokawa M, et al. Nutraceutical characteristics of the brown seaweed carotenoid fucoxanthin[J]. Archives of biochemistry and biophysics, 2020, 686: 108364.
[4] Šudomová M, Shariati M A, Echeverría J, et al. A microbiological, toxicological, and biochemical study of the effects of fucoxanthin, a marine carotenoid, on Mycobacterium tuberculosis and the enzymes implicated in its cell wall: A link between mycobacterial infection and autoimmune diseases[J]. Marine drugs, 2019, 17(11): 641.
[5] Chung T W, Choi H J, Lee J Y, et al. Marine algal fucoxanthin inhibits the metastatic potential of cancer cells[J]. Biochemical and biophysical research communications, 2013, 439(4): 580-585.
[6] Ye G, Wang L, Yang K, et al. Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D[J]. Journal of International Medical Research, 2020, 48(10): 0300060520964011.
[7] Shiratori K, Ohgami K, Ilieva I, et al. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo[J]. Experimental eye research, 2005, 81(4): 422-428.
[8] Yang H, Xing R, Liu S, et al. Role of Fucoxanthin towards Cadmium-induced renal impairment with the antioxidant and anti-lipid peroxide activities[J]. Bioengineered, 2021, 12(1): 7235-7247.
| Cell experiment [1]: | |
Cell lines | B16-F10 cells |
Preparation Method | 100μL of 0.2% collagen-fragmented gelatin was applied to the upper side of the filter. Serum-free DMEM (with or without Fucoxanthin (0, 5,10, 30μM)) was added to the lower part of the chamber. The chamber was incubated at 37°C in a 5% CO2 atmosphere for 24h. After incubation, the filter insert was removed from the chamber wells and cells on the upper side of the filter were removed using a cotton swab. The filter was fixed, stained with hematoxylin and eosin, and mounted on a microscope slide. Cells located on the lower side of the filter were counted to determine whether they were invasive cells. |
Reaction Conditions | 0, 5,10, 30μM; 24h |
Applications | Fucoxanthin resulted in a significant decrease in the number of invaded B16-F10 cells. |
| Animal experiment [2]: | |
Animal models | Kunming mice |
Preparation Method | Total animals (N=120) were randomly divided into two groups of equal average body weight. The mice of the control group (N=20) were given pure water only, whereas the animals of the cadmium exposure group (N=100) were given CdCl2 orally at a dose of 30mg/kg/day for 30 days. In this study, Fucoxanthin was administered at 10, 25 and 50mg/kg/day. To evaluate ameliorative effects of Fucoxanthin on the kidney, the cadmium exposure group was divided into the following five subgroups: without Fucoxanthin treatment as a negative control group (NCG); positive control group (PCG) was mice received Shenfukang tablets orally at a dose of 50mg/kg/day for 14 days; low (F1), medium (F2), and high (F3) Fucoxanthin concentration treated mice were received Fucoxanthin orally at a dose of 10, 25, and 50mg/kg/day for 14 days, respectively. After the 14-day Fucoxanthin treatment, mice were sacrificed. Kidney tissues and peripheral blood samples were collected directly. |
Dosage form | 10, 25, 50mg/kg/day for 14 days; p.o. |
Applications | High doses of Fucoxanthin administration significantly decreased BUN, KIM1, NGAL levels, increasing POD, SOD, CAT, and ascorbate APX levels. Fucoxanthin administration also promoted recovery of the renal functions, micro-structural organization, and ultra-structural organization in the renal cells. |
References: | |
| Cas No. | 3351-86-8 | SDF | |
| Canonical SMILES | O=C(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C([H])=[C@@]=C([C@@]1(O)C)C(C)(C[C@H](OC(C)=O)C1)C)C[C@]2(C3(C)C)[C@@](C)(C[C@@H](O)C3)O2 | ||
| Formula | C42H58O6 | M.Wt | 658.91 |
| Solubility | DMSO : ≥ 50 mg/mL (75.88 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5177 mL | 7.5883 mL | 15.1766 mL |
| 5 mM | 0.3035 mL | 1.5177 mL | 3.0353 mL |
| 10 mM | 0.1518 mL | 0.7588 mL | 1.5177 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *